Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Clin Cancer Res. 2022 Sep 15;28(18):3958-3964. doi: 10.1158/1078-0432.CCR-22-0964.
Clin Cancer Res. 2022.
PMID: 35852793
Free PMC article.
Clinical Trial.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos JC, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker L, Fonseca GA, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao P, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM.
Mato AR, et al. Among authors: paskalis d.
Blood. 2021 May 20;137(20):2817-2826. doi: 10.1182/blood.2020007376.
Blood. 2021.
PMID: 33259589
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.